Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
TopGum has completed the acquisition of P&L Developments, a pharmacy business in New York, for $35 million. TopGum acquires P&L Developments to expand into pharmaceutical gummies and add a U.S.-based manufacturing platform built to FDA pharmaceutical standards. P&L Developments’ gummy operations support the production of healthcare products for OTC and retailer store-brand distribution, strengthening TopGum’s U.S. market presence. The healthcare M&A transaction is an add on acquisition and strategic acquisition by a strategic buyer, with a long-term commercial partnership where PLD will commercialize and distribute TopGum-manufactured products to leading U.S. retailers. The deal was first announced via a binding letter of intent in January 2026 and closed in May 2026.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026